245 related articles for article (PubMed ID: 29117945)
1. Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin.
Sheng X; Parmentier JH; Tucci J; Pei H; Cortez-Toledo O; Dieli-Conwright CM; Oberley MJ; Neely M; Orgel E; Louie SG; Mittelman SD
Mol Cancer Res; 2017 Dec; 15(12):1704-1713. PubMed ID: 29117945
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.
Quiñones-Lombraña A; Ferguson D; Hageman Blair R; Kalabus JL; Redzematovic A; Blanco JG
Pharm Res; 2014 Jul; 31(7):1644-55. PubMed ID: 24562808
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
[TBL] [Abstract][Full Text] [Related]
5. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
7. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
Palackal NT; Lee SH; Harvey RG; Blair IA; Penning TM
J Biol Chem; 2002 Jul; 277(27):24799-808. PubMed ID: 11978787
[TBL] [Abstract][Full Text] [Related]
8. Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response.
Sheng X; Tucci J; Parmentier JH; Ji L; Behan JW; Heisterkamp N; Mittelman SD
Oncotarget; 2016 Nov; 7(45):73147-73159. PubMed ID: 27705905
[TBL] [Abstract][Full Text] [Related]
9. Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells.
Matsunaga T; Yamaguchi A; Morikawa Y; Kezuka C; Takazawa H; Endo S; El-Kabbani O; Tajima K; Ikari A; Hara A
Anticancer Drugs; 2014 Sep; 25(8):868-77. PubMed ID: 24743520
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases.
Bajraktari-Sylejmani G; Oster JS; Burhenne J; Haefeli WE; Sauter M; Weiss J
Arch Toxicol; 2024 Mar; 98(3):807-820. PubMed ID: 38175295
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
12. Daunorubicin reductase activity in human normal lymphocytes, myeloblasts and leukemic cell lines.
Ahmed NK
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1209-13. PubMed ID: 3908117
[TBL] [Abstract][Full Text] [Related]
13. Uptake and metabolism of daunorubicin by human myelocytic cells.
Vasanthakumar G; Ahmed NK
Cancer Chemother Pharmacol; 1985; 15(1):35-9. PubMed ID: 3891121
[TBL] [Abstract][Full Text] [Related]
14. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Lewis MJ; Wiebe JP; Heathcote JG
BMC Cancer; 2004 Jun; 4():27. PubMed ID: 15212687
[TBL] [Abstract][Full Text] [Related]
15. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases.
Malátková P; Sokolová S; Chocholoušová Havlíková L; Wsól V
Biochem Pharmacol; 2016 Jun; 109():83-90. PubMed ID: 27055738
[TBL] [Abstract][Full Text] [Related]
16. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.
Gonzalez B; Akman S; Doroshow J; Rivera H; Kaplan WD; Forrest GL
Cancer Res; 1995 Oct; 55(20):4646-50. PubMed ID: 7553643
[TBL] [Abstract][Full Text] [Related]
17. Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1.
Hintzpeter J; Hornung J; Ebert B; Martin HJ; Maser E
Chem Biol Interact; 2015 Jun; 234():162-8. PubMed ID: 25541467
[TBL] [Abstract][Full Text] [Related]
18. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.
Steckelbroeck S; Oyesanmi B; Jin Y; Lee SH; Kloosterboer HJ; Penning TM
J Pharmacol Exp Ther; 2006 Mar; 316(3):1300-9. PubMed ID: 16339391
[TBL] [Abstract][Full Text] [Related]
19. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
[TBL] [Abstract][Full Text] [Related]
20. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes.
Plebuch M; Soldan M; Hungerer C; Koch L; Maser E
Cancer Lett; 2007 Sep; 255(1):49-56. PubMed ID: 17482758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
